Webinar

Using FDA’s Draft Guidance on Risk-Based Monitoring to Improve Clinical Data Quality

Published

Format: External webinar | Document type: Webinar

Using FDA’s Draft Guidance on Risk-Based Monitoring to Improve Clinical Data Quality
The Industry’s changing approach to clinical data monitoring requires the tools and team structure to effectively plan and execute risk-based monitoring. Join Lynn King and Rob Woolson as they discuss multi-disciplinary approaches to implementing alternative monitoring plans and specialized tools for successfully executing risk-based monitoring.

Speakers

Lynn King, Assistant Vice President, Operations, Rho Lynn King Assistant Vice President, Operations
Rho

Rob Woolson, MS, Senior Biostatistician, Rho Rob Woolson, MS Senior Biostatistician
Rho

Related resources from Rho

Supplier info centre